Clinical and echocardiographic outcome in patients receiving carvedilol for treatment of dilated cardiomyopathy.
To determine outcome of children receiving carvedilol in addition to other standard drug therapy for treatment of dilated cardiomyopathy. Children receiving carvedilol for treatment of dilated cardiomyopathy with moderate to severe ventricular dysfunction were included into the study. Data on history, clinical examination and investigations were obtained and detailed echocardiography findings were recorded for the initial and all subsequent visits. Thirty-three children, mean age 26 ± 30 mo (range 7 mo to 138 mo) were enrolled. Carvedilol was initiated at a mean dose of 0.14 ± 0.03 mg/kg/d and the maintenance dose was 0.46 ± 0.14 mg/kg/d. At a follow up of 6-90 mo (mean of 28 ± 23 mo), functional class using Ross classification for pediatric heart failure improved from 2.7 to 1.3. The left ventricular ejection fraction rose from a basal value of 22 % ± 7 % (10-40 %) to 42 % ± 15 % (15-65 %) (p < 0.0001). Similarly, left ventricular fractional shortening increased significantly from 16 ± 6 % (8-34 %) to 21 ± 7 % (10-44 %) (p < 0.0001). One patient deteriorated and died of refractory heart failure. Carvedilol was discontinued in two more patients temporarily due to bronchospasm during respiratory infection. The present study suggests that improvement in ventricular function and clinical symptoms is seen on oral carvedilol added to standard drug therapy in pediatric patients with dilated cardiomyopathy and moderate to severe ventricular dysfunction. The drug is well tolerated with minimal side effects but close monitoring is required as it may worsen heart failure and bronchospasm.